Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics’ colorectal cancer screening test Epi proColon(R)

Epigenomics AG / Key word(s): Miscellaneous

Epigenomics AG: Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics’ colorectal cancer screening test Epi proColon(R)

09-Jun-2018 / 12:20 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Publication of Inside Information according to Article 17 MAR

Centers for Medicare & Medicaid Services publish preliminary rate of $192 for Epigenomics’ colorectal cancer screening test Epi proColon(R)

June 9, 2018 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved blood-based test for colorectal cancer screening. A press release with further details will be published on Monday, June 11, 2018.

Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 


09-Jun-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this